SCHEMBL4969174

SCHEMBL4969174

O=C(NCC(c1ccccc1)(c1ccc(F)cc1)c1cc(F)cc(C(F)(F)F)c1)C(O)(O)C(F)(F)F

nearest known ligand 0.48

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CETP P11597 7/20 0.48
KCNH2 Q12809 4/20 0.44
SLC6A9 P48067 1/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
MEN1 O00255 1/20 0.39
ALDH1A1 P00352 1/20 0.39
LMNA P02545 1/20 0.39
POLB P06746 1/20 0.39
KMT2A Q03164 1/20 0.39
P2RX1 P51575 1/20 0.39
TACR1 P25103 4/20 0.38
VNN1 O95497 1/20 0.36
HTT P42858 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
KCNN4 O15554 2/20 0.36
RXRA P19793 1/20 0.36
RXRB P28702 1/20 0.36
RXRG P48443 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4971187 0.80 CETP (0.65) CETPKCNH2SLC6A9SMN1; SMN2MEN1
SCHEMBL4721472 0.80 CETP (0.41) CETPKCNH2SLC6A9SMN1; SMN2MEN1
SCHEMBL4966775 0.79 CETP (0.43) CETPKCNH2SLC6A9P2RX1TACR1
SCHEMBL4967551 0.79 CETP (0.43) CETPKCNH2SLC6A9P2RX1TACR1
SCHEMBL4970220 0.79 CETP (0.43) CETPKCNH2SLC6A9P2RX1TACR1
SCHEMBL4969024 0.78 CETP (0.66) CETPKCNH2SLC6A9SMN1; SMN2MEN1
SCHEMBL4716662 0.76 DDR1 (0.40) CETPKCNH2SLC6A9LMNAPOLB
SCHEMBL757654 0.75 CETP (0.70) CETPKCNH2
SCHEMBL757655 0.75 CETP (0.70) CETPKCNH2
SCHEMBL757766 0.75 CETP (0.70) CETPKCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1954668-A2 HOMO- AND HETEROCYCLIC COMPOUNDS SUITABLE AS CETP INHIBITORS Brystol-Myers Squibb Company (US) 2008-08-13 EP disclosed
WO-2007062308-A2 HOMO- AND HETEROCYCLIC COMPOUNDS SUITABLE AS CETP INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2007-05-31 WO disclosed